ME00937B - Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera - Google Patents
Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kanceraInfo
- Publication number
- ME00937B ME00937B MEP-2009-304A MEP30409A ME00937B ME 00937 B ME00937 B ME 00937B ME P30409 A MEP30409 A ME P30409A ME 00937 B ME00937 B ME 00937B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- compound
- chemotherapeutic agent
- treatment
- small cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 201000011510 cancer Diseases 0.000 title claims 8
- 238000011282 treatment Methods 0.000 title claims 7
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002456 taxol group Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Jedinjenje koje je: ili njegov pojedinačni izomer ili tautomer gde je jedinjenje izborno kao njegova farmaceutski prihvatljiva so i dodatno izborno kao hidrat i dodatno izborno kao solvat; za upotrebu u kombinaciji sa jednim ili više tretmana nezavisno izabranih od jednog ili više hemoterapeutskih sredstava izabranih iz grupe koju čine platin, taksan, rapamicin i erlotinib za lečenje kancera.
2. Jedinjenje ili njegov pojedinačni izomer ili tautomer prema patentnom zahtevu 1, naznačeno time što je kancer izabran iz grupe koju čine kancer dojke, kancer debelog creva, kancer rektuma, kancer endometrijuma, gastrointestinalni karcinoidni tumori, gastrointestinalni stromalni tumori, glioblastom, hepatoćelijski karcinom, sitnoćelijski kancer pluća, nesitnoćelijski kancer pluća, melanom, kancer jajnika, kancer grlića materice, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija, hronična mijelogena leukemija, ne-Hodčkinov limfom i karcinom tireoidee.
3. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je tretman jedno hemoterapeutsko sredstvo, gdejehemoterapeutsko sredstvo taksol.
4. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je tretman jedno hemoterapeutsko sredstvo, gde je hemoterapeutsko sredstvo rapamicin.
5. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je tretman jedno hemoterapeutsko sredstvo, gdejehemoterapeutsko sredstvo karboplatin.
6. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je tretman jedno hemoterapeutsko sredstvo, gde je hemoterapeutsko sredstvo erlotinib.
7. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je kancer izabran od kancera prostate, nesitnoćelijskog kancera pluća i kancera dojke.
8. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je hemoterapeutsko sredstvo taksol i kancer je kancer prostate.
9. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je hemoterapeutsko sredstvo rapamicin i kancer je kancer prostate.
10. Jedinjenje prema patentnom zahtevu 1, naznačeno time je hemoterapeutsko sredstvo karboplatin i kancer je nesitnoćelijski kancer pluća.
11. Jedinjenje prema patentnom zahtevu 1, naznačeno time stoje hemoterapeutsko sredstvo erlotinib i kancer je kancer dojke.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92316407P | 2007-04-11 | 2007-04-11 | |
| PCT/US2008/004570 WO2008127594A2 (en) | 2007-04-11 | 2008-04-08 | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00937B true ME00937B (me) | 2012-06-20 |
Family
ID=39864581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-304A ME00937B (me) | 2007-04-11 | 2008-04-08 | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8481001B2 (me) |
| EP (1) | EP2139483B9 (me) |
| JP (2) | JP5726515B2 (me) |
| KR (1) | KR101586774B1 (me) |
| CN (2) | CN103202842A (me) |
| AU (1) | AU2008239668B2 (me) |
| BR (1) | BRPI0810208A2 (me) |
| CA (1) | CA2684056A1 (me) |
| CO (1) | CO6140024A2 (me) |
| CR (1) | CR11099A (me) |
| CY (1) | CY1114608T1 (me) |
| DK (1) | DK2139483T3 (me) |
| EA (1) | EA019064B1 (me) |
| EC (1) | ECSP099723A (me) |
| ES (1) | ES2438998T3 (me) |
| GT (1) | GT200900263A (me) |
| HR (1) | HRP20131081T1 (me) |
| IL (1) | IL201211A (me) |
| MA (1) | MA31335B1 (me) |
| ME (1) | ME00937B (me) |
| MX (1) | MX2009010929A (me) |
| MY (1) | MY150797A (me) |
| NI (1) | NI200900184A (me) |
| NZ (1) | NZ580009A (me) |
| PL (1) | PL2139483T3 (me) |
| PT (1) | PT2139483E (me) |
| RS (1) | RS53020B (me) |
| SI (1) | SI2139483T1 (me) |
| SV (1) | SV2009003390A (me) |
| TN (1) | TN2009000399A1 (me) |
| UA (1) | UA98141C2 (me) |
| WO (1) | WO2008127594A2 (me) |
| ZA (1) | ZA200906765B (me) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1931645B1 (en) * | 2005-10-07 | 2014-07-16 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| KR20140105621A (ko) * | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | ＰＩ３Ｋα의 피리도피리미디논 억제제 |
| AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| KR101626435B1 (ko) * | 2007-04-10 | 2016-06-01 | 엑셀리시스, 인코포레이티드 | Ｐｉ３ｋ 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법 |
| US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
| DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| UY33221A (es) | 2010-02-09 | 2011-09-30 | Univ California | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA |
| EA201390085A1 (ru) | 2010-07-09 | 2013-06-28 | Экселиксис, Инк. | Композиции ингибиторов киназ для лечения рака |
| AU2011302196B2 (en) | 2010-09-14 | 2016-04-28 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| BR112013009643A2 (pt) | 2010-10-20 | 2016-07-19 | Merck Serono S A Geneva | método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas |
| DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
| WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| UY34339A (es) * | 2011-09-14 | 2013-04-30 | Exelixis Inc | Inhibidores de la fosfatidilinositol 3-quinasa para el tratamiento del cancer |
| WO2013052699A2 (en) * | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| WO2013056067A1 (en) | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| BR112014009993A2 (pt) * | 2011-10-28 | 2017-04-25 | Novartis Ag | método para o tratamento de tumores do estroma gastrointestinal |
| WO2013067141A1 (en) | 2011-11-01 | 2013-05-10 | Exelixis, Inc. | N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies |
| WO2013067306A1 (en) * | 2011-11-02 | 2013-05-10 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
| WO2013101964A1 (en) * | 2011-12-27 | 2013-07-04 | Kadmon Corporation, Llc | Methods for treatment of breast cancer nonresponsive to trastuzumab |
| CN103467482B (zh) | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| JP6193374B2 (ja) | 2012-08-13 | 2017-09-06 | 武田薬品工業株式会社 | Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体 |
| CN104513254B (zh) | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| CN106831722B (zh) | 2013-10-16 | 2019-08-30 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| WO2015123505A1 (en) | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| WO2019119206A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
| WO2007023186A1 (en) * | 2005-08-26 | 2007-03-01 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
| KR20140105621A (ko) * | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | ＰＩ３Ｋα의 피리도피리미디논 억제제 |
| EP1931645B1 (en) * | 2005-10-07 | 2014-07-16 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| ZA200904857B (en) * | 2007-02-22 | 2010-09-29 | Merck Serono Sa | Quinoxaline compounds and use thereof |
| KR101626435B1 (ko) * | 2007-04-10 | 2016-06-01 | 엑셀리시스, 인코포레이티드 | Ｐｉ３ｋ 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법 |
| JP4623164B2 (ja) * | 2008-08-21 | 2011-02-02 | セイコーエプソン株式会社 | プロジェクタ |
-
2008
- 2008-04-08 US US12/595,236 patent/US8481001B2/en not_active Expired - Fee Related
- 2008-04-08 JP JP2010503043A patent/JP5726515B2/ja active Active
- 2008-04-08 CN CN2013101161222A patent/CN103202842A/zh active Pending
- 2008-04-08 EA EA200970935A patent/EA019064B1/ru not_active IP Right Cessation
- 2008-04-08 CN CN2008800173944A patent/CN101959516B/zh not_active Expired - Fee Related
- 2008-04-08 WO PCT/US2008/004570 patent/WO2008127594A2/en not_active Ceased
- 2008-04-08 PL PL08742674T patent/PL2139483T3/pl unknown
- 2008-04-08 KR KR1020097023536A patent/KR101586774B1/ko not_active Expired - Fee Related
- 2008-04-08 NZ NZ580009A patent/NZ580009A/xx not_active IP Right Cessation
- 2008-04-08 HR HRP20131081AT patent/HRP20131081T1/hr unknown
- 2008-04-08 RS RS20130486A patent/RS53020B/sr unknown
- 2008-04-08 BR BRPI0810208-2A2A patent/BRPI0810208A2/pt not_active IP Right Cessation
- 2008-04-08 PT PT87426748T patent/PT2139483E/pt unknown
- 2008-04-08 ES ES08742674.8T patent/ES2438998T3/es active Active
- 2008-04-08 SI SI200831061T patent/SI2139483T1/sl unknown
- 2008-04-08 MX MX2009010929A patent/MX2009010929A/es active IP Right Grant
- 2008-04-08 AU AU2008239668A patent/AU2008239668B2/en not_active Ceased
- 2008-04-08 EP EP08742674.8A patent/EP2139483B9/en active Active
- 2008-04-08 DK DK08742674.8T patent/DK2139483T3/da active
- 2008-04-08 MY MYPI20094215 patent/MY150797A/en unknown
- 2008-04-08 CA CA002684056A patent/CA2684056A1/en not_active Abandoned
- 2008-04-08 UA UAA200911452A patent/UA98141C2/ru unknown
- 2008-04-08 ME MEP-2009-304A patent/ME00937B/me unknown
-
2009
- 2009-09-29 IL IL201211A patent/IL201211A/en active IP Right Grant
- 2009-09-29 ZA ZA200906765A patent/ZA200906765B/xx unknown
- 2009-09-30 TN TNP2009000399A patent/TN2009000399A1/fr unknown
- 2009-10-09 GT GT200900263A patent/GT200900263A/es unknown
- 2009-10-09 NI NI200900184A patent/NI200900184A/es unknown
- 2009-10-09 SV SV2009003390A patent/SV2009003390A/es unknown
- 2009-10-30 MA MA32313A patent/MA31335B1/fr unknown
- 2009-11-09 CO CO09126923A patent/CO6140024A2/es unknown
- 2009-11-09 EC EC2009009723A patent/ECSP099723A/es unknown
- 2009-11-09 CR CR11099A patent/CR11099A/es unknown
-
2013
- 2013-11-01 JP JP2013228684A patent/JP2014074031A/ja active Pending
- 2013-11-15 CY CY20131101016T patent/CY1114608T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| JP2010523670A5 (me) | ||
| MX2011012584A (es) | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. | |
| JP2018140982A5 (me) | ||
| IL201284A (en) | K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| AR085718A1 (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida | |
| JP2009514880A5 (me) | ||
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| MY156210A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| NZ596365A (en) | Pentamidine combinations for treating cancer | |
| JP2010501572A5 (me) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| NZ608667A (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| AR074575A1 (es) | Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer | |
| PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
| MY144045A (en) | Methods of treating cancer and related methods | |
| NZ731797A (en) | Dna-pk inhibitors | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| GEP201706691B (en) | Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1 | |
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака | |
| JP2016520528A5 (me) |